ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
의약품 재이용 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 373억 8,000만 달러에서 2026년에는 409억 5,000만 달러로, CAGR 9.6%로 확대될 전망입니다. 지난 수년간의 성장은 기존 신약개발의 고비용 및 장기화, 실패하는 약물 후보물질의 증가, 만성질환 및 희귀질환의 유병률 증가, 신흥질환에 대한 치료옵션의 제한, 약물 재창출을 위한 계산기법의 조기 도입 등이 요인으로 작용한 것으로 보입니다.
약제 재사용 시장 규모는 향후 몇 년간 강력한 성장할 것으로 예상됩니다. 2030년에는 583억 3,000만 달러에 달하고, CAGR은 9.2%가 될 전망입니다. 예측 기간 동안의 성장 요인으로는 AI와 머신러닝의 신약 전환에 대한 통합, 바이오테크 및 제약 연구에 대한 투자 확대, CRO(임상시험수탁기관)의 역량 강화, 저렴한 치료법에 대한 수요 증가, 전환 의약품 승인에 대한 규제적 지원 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 표현형 및 표적 기반 스크리닝에 대한 관심 증가, 구조 기반 약물 재배치 채택 증가, 표적 외 활성 확인 방법의 성장, 희귀 질환 및 감염성 질환에 대한 약물 재사용 확대, 기존 분자를 이용한 신약 개발 기간 단축 등이 있습니다.
신경퇴행성 질환의 발생률 증가는 향후 몇 년 동안 약물 전환 시장 확대를 촉진하는 요인이 될 것으로 예상됩니다. 신경퇴행성 질환은 신경세포의 구조나 기능이 점진적으로 악화되어 결국 신경세포가 죽게 되는 일련의 질환군을 말합니다. 알츠하이머형 치매와 같은 신경퇴행성 질환의 증가는 주로 평균수명의 연장에 기인합니다. 노화는 신경 기능의 점진적인 저하를 초래하는 주요 위험 요소이기 때문입니다. 약물 재창출은 안전성 프로파일이 확립된 기존 의약품을 발굴하고 관련 질병 경로를 표적으로 전환하여 신경퇴행성 질환의 관리를 돕고 효과적인 치료법 개발을 가속화합니다. 예를 들어, 미국에 본사를 둔 비영리 자율 건강 단체인 알츠하이머병 협회에 따르면, 2023년 3월 기준 65세 이상 미국인 약 670만 명이 알츠하이머병에 걸렸으며, 이 숫자는 2060년까지 1,380만 명으로 늘어날 것으로 예측하고 있습니다. 이 때문에 신경퇴행성 질환의 유병률 증가는 약물 전환 시장의 성장을 촉진하고 있습니다.
의약품 재이용 시장에서 활동하는 주요 기업들은 기존 의약품의 새로운 치료 용도 발굴을 가속화하기 위해 인공지능(AI)을 활용한 약물-단백질 상호작용 모델링과 같은 첨단 기술 개발에 집중하고 있습니다. AI를 활용한 약물-단백질 상호작용 모델링은 인공지능과 머신러닝 기술을 이용하여 인간 단백질체 전체에서 약물과 단백질의 상호작용을 예측합니다. 대규모 데이터세트를 활용하여 정확도와 신뢰성을 향상시키고 있습니다. 예를 들어, 2025년 7월 미국 헬스케어 기업 코스모스 헬스(Cosmos Health)는 약물 전환을 위해 설계된 첨단 AI 플랫폼 '클라우즈스크린 2.0(Cloudscreen 2.0)'을 발표했습니다. 이 차세대 시스템은 기존 대비 100배 이상의 대규모 데이터세트를 처리할 수 있으며, 약물과 단백질의 상호작용에 대한 상세한 분석이 가능합니다. 돌연변이 유발 데이터와 무질서 단백질 연구 도구를 통합하여 암, 비만, 당뇨 등의 질병을 대상으로 하고 있습니다. 또한, 그래픽처리장치(GPU) 기반의 클라우드 컴퓨팅을 통해 확장 가능한 데이터 처리를 실현하고, 다양한 치료 영역의 약물 전환 R&D 파이프라인을 가속화하는 데 있어 본 플랫폼은 중요한 혁신 기술로 자리매김하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 시장에서 세계의 총 잠재 시장 규모(TAM)
제9장 시장 세분화
제10장 지역별, 국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자 환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업과 혁신적 기업
제38장 세계의 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
KSM
영문 목차
영문목차
Drug repurposing involves discovering new therapeutic applications for existing or previously unsuccessful drugs. It utilizes established safety data and known pharmacological properties to shorten development timelines and lower costs. The objective is to accelerate the availability of treatments by avoiding the initial stages of drug discovery.
The primary forms of drug repurposing include disease-centric, target-centric, and drug-centric approaches. Disease-centric repurposing focuses on a particular disease and evaluates a range of existing drugs to determine their effectiveness in treating that condition, irrespective of their original biological targets. The drug molecules involved include biologics and small molecules. Therapeutic areas covered include oncology, neurology, infectious diseases, cardiovascular diseases, and autoimmune disorders, delivered through routes of administration such as oral, intravenous, topical, inhalation, and intramuscular, and serving end users including pharmaceutical companies, research and academic institutions, and contract research organizations.
Tariffs have affected the drug repurposing market by increasing costs for imported laboratory equipment, biologics, and research reagents, impacting segments such as biologics and small molecule repurposing. Regions like North America, Europe, and Asia-Pacific manufacturing hubs face increased import duties, leading to higher R&D expenses. However, tariffs have also encouraged local production of research tools, promoted domestic innovation, and improved investment in in-house repurposing capabilities, helping companies maintain long-term competitiveness.
The drug repurposing market research report is one of a series of new reports from The Business Research Company that provides drug repurposing market statistics, including drug repurposing industry global market size, regional shares, competitors with a drug repurposing market share, detailed drug repurposing market segments, market trends and opportunities, and any further data you may need to thrive in the drug repurposing industry. This drug repurposing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The drug repurposing market size has grown strongly in recent years. It will grow from $37.38 billion in 2025 to $40.95 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to high cost and time of traditional drug discovery, increasing number of failed drug candidates, rising prevalence of chronic and rare diseases, limited therapeutic options for emerging diseases, early adoption of computational methods for drug repositioning.
The drug repurposing market size is expected to see strong growth in the next few years. It will grow to $58.33 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to integration of ai and machine learning in drug repurposing, growing investment in biotech and pharma research, expansion of contract research organizations (cros) capabilities, rising demand for affordable therapies, regulatory support for repurposed drug approvals. Major trends in the forecast period include increasing focus on phenotypic and target-based screening, rising adoption of structure-based drug repositioning, growth in off-target activity identification approaches, expansion of drug repurposing for rare and infectious diseases, shortening drug development timelines through existing molecules.
The rising incidence of neurodegenerative diseases is anticipated to drive the expansion of the drug repurposing market in the coming years. Neurodegenerative diseases encompass a group of disorders marked by the progressive deterioration of neuron structure or function, ultimately leading to neuronal death. The increasing occurrence of neurodegenerative conditions, such as Alzheimer's dementia, is largely attributed to longer life expectancy, as aging is the primary risk factor contributing to the gradual decline of neuronal function over time. Drug repurposing supports the management of neurodegenerative diseases by identifying existing medications with established safety profiles that can be redirected to target relevant disease pathways, thereby speeding up the development of effective therapies. For example, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia in 2023, with projections estimating this number will rise to 13.8 million by 2060. Consequently, the growing prevalence of neurodegenerative diseases is fueling the growth of the drug repurposing market.
Key companies operating in the drug repurposing market are emphasizing the development of advanced technologies, such as artificial intelligence (AI)-driven drug-protein interaction modeling, to accelerate the discovery of new therapeutic applications for existing drugs. AI-powered drug-protein interaction modeling utilizes artificial intelligence and machine learning techniques to predict how drugs interact with proteins across the human proteome, drawing on large-scale datasets to improve accuracy and reliability. For instance, in July 2025, Cosmos Health Inc., a US-based healthcare company, launched Cloudscreen 2.0, an advanced AI platform designed for drug repurposing. This next-generation system is capable of processing datasets more than 100 times larger than earlier versions, enabling in-depth analysis of drug-protein interactions. By integrating mutagenesis data and tools for studying disordered proteins, the platform targets diseases including cancer, obesity, and diabetes. Furthermore, graphics processing unit (GPU)-based cloud computing enables scalable data processing, positioning the platform as a significant innovation in accelerating research and development pipelines for drug repurposing across diverse therapeutic areas.
In July 2025, Predictive Oncology Inc., a US-based artificial intelligence-driven drug discovery and repurposing company, entered into a partnership with YA II PN, Ltd., securing a $10 million share purchase agreement. Through this collaboration, Predictive Oncology seeks to further develop its AI-driven platform to speed up the identification of new therapeutic uses for existing drugs and to streamline oncology drug discovery workflows. YA II PN, Ltd. is a US-based investment fund managed by Yorkville Advisors Global, LP, a US-based investment management firm that provides financing to support such initiatives.
Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.
North America was the largest region in the drug repurposing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the drug repurposing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The drug repurposing market consists of revenues earned by entities by providing services such as computational drug screening, clinical trial design and support, regulatory consulting, bioinformatics analysis, and data mining of existing drug databases. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug repurposing market also includes sales of thalidomide, sildenafil, minoxidil, metformin, and azithromycin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Drug Repurposing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses drug repurposing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for drug repurposing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug repurposing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Type: Disease-Centric; Target-Centric; Drug-Centric
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
4.1.4 Industry 4.0 & Intelligent Manufacturing
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Increasing Focus On Phenotypic And Target-Based Screening
4.2.2 Rising Adoption Of Structure-Based Drug Repositioning
4.2.3 Growth In Off-Target Activity Identification Approaches
4.2.4 Expansion Of Drug Repurposing For Rare And Infectious Diseases
4.2.5 Shortening Drug Development Timelines Through Existing Molecules
5. Drug Repurposing Market Analysis Of End Use Industries
5.1 Pharmaceutical Companies
5.2 Research And Academic Institutes
5.3 Contract Research Organizations (Cros)
5.4 Biotechnology Companies
5.5 Hospitals And Clinical Research Centers
6. Drug Repurposing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Drug Repurposing Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Drug Repurposing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Drug Repurposing Market Size, Comparisons And Growth Rate Analysis
7.3. Global Drug Repurposing Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Drug Repurposing Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Drug Repurposing Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Drug Repurposing Market Segmentation
9.1. Global Drug Repurposing Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Disease-Centric, Target-Centric, Drug-Centric
9.2. Global Drug Repurposing Market, Segmentation By Drug Molecules, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Biologics, Small Molecule
9.3. Global Drug Repurposing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.7. Global Drug Repurposing Market, Sub-Segmentation Of Target-Centric, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting
9.8. Global Drug Repurposing Market, Sub-Segmentation Of Drug-Centric, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing
10. Drug Repurposing Market Regional And Country Analysis
10.1. Global Drug Repurposing Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Drug Repurposing Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Drug Repurposing Market
11.1. Asia-Pacific Drug Repurposing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Drug Repurposing Market
12.1. China Drug Repurposing Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Drug Repurposing Market
13.1. India Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Drug Repurposing Market
14.1. Japan Drug Repurposing Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Drug Repurposing Market
15.1. Australia Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Drug Repurposing Market
16.1. Indonesia Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Drug Repurposing Market
17.1. South Korea Drug Repurposing Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Drug Repurposing Market
18.1. Taiwan Drug Repurposing Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Drug Repurposing Market
19.1. South East Asia Drug Repurposing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Drug Repurposing Market
20.1. Western Europe Drug Repurposing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Drug Repurposing Market
21.1. UK Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Drug Repurposing Market
22.1. Germany Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Drug Repurposing Market
23.1. France Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Drug Repurposing Market
24.1. Italy Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Drug Repurposing Market
25.1. Spain Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Drug Repurposing Market
26.1. Eastern Europe Drug Repurposing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Drug Repurposing Market
27.1. Russia Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Drug Repurposing Market
28.1. North America Drug Repurposing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Drug Repurposing Market
29.1. USA Drug Repurposing Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Drug Repurposing Market
30.1. Canada Drug Repurposing Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Drug Repurposing Market
31.1. South America Drug Repurposing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Drug Repurposing Market
32.1. Brazil Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Drug Repurposing Market
33.1. Middle East Drug Repurposing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Drug Repurposing Market
34.1. Africa Drug Repurposing Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Drug Repurposing Market, Segmentation By Type, Segmentation By Drug Molecules, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Drug Repurposing Market Regulatory and Investment Landscape
36. Drug Repurposing Market Competitive Landscape And Company Profiles
36.1. Drug Repurposing Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Drug Repurposing Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Drug Repurposing Market Company Profiles
36.3.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.5. Teva Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis
37. Drug Repurposing Market Other Major And Innovative Companies
Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.
38. Global Drug Repurposing Market Competitive Benchmarking And Dashboard
39. Key Mergers And Acquisitions In The Drug Repurposing Market
40. Drug Repurposing Market High Potential Countries, Segments and Strategies
40.1 Drug Repurposing Market In 2030 - Countries Offering Most New Opportunities
40.2 Drug Repurposing Market In 2030 - Segments Offering Most New Opportunities
40.3 Drug Repurposing Market In 2030 - Growth Strategies
